Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD).
In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist.
Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome.
Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE).
The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 268 |
| CEO | Jeffrey Dayno |
Contact Details
Address: 630 West Germantown Pike, Suite 215 Plymouth Meeting, Pennsylvania 19462 United States | |
| Phone | 484 539 9800 |
| Website | harmonybiosciences.com |
Stock Details
| Ticker Symbol | HRMY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001802665 |
| CUSIP Number | 413197104 |
| ISIN Number | US4131971040 |
| Employer ID | 82-2279923 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer and Director |
| Jeffrey S. Aronin | Founder and Non-Executive Chairman |
| Dr. Kumar Budur M.D., M.S. | Executive Vice President and Chief Medical and Scientific Officer |
| Jeffrey Dierks M.B.A. | Executive Vice President and Chief Commercial Officer |
| Andrew Serafin J.D., M.B.A. | Executive Vice President and Chief Strategy Officer |
| David Bradshaw | Head of Technical Operations |
| Brennan Doyle | Vice President and Head of Investor Relations |
| Christian Ulrich J.D. | General Counsel and Corporate Secretary |
| Tricia Glover | Chief Compliance Officer |
| Audrey Murphy SPHR | Vice Presidet of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 144 | Filing |
| Feb 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Jan 30, 2025 | SCHEDULE 13G/A | Filing |